An international meta-analysis detailed the efficacy and safety profile of tirzepatide—a dual GIP and GLP-1 receptor agonist—unveiling its marked benefits for weight loss across multiple populations, including patients with and without type 2 diabetes. The analysis consolidates evidence for tirzepatide’s role in metabolic therapeutics, offering clinicians an efficacious option for comprehensive weight management and glycemic control.